User profiles for "author:Marc Scherlinger"
 | Marc SCHERLINGERStrasbourg University Hospital (HUS) Verified email at chu-bordeaux.fr Cited by 1001 |
[HTML][HTML] The role of platelets in immune-mediated inflammatory diseases
M Scherlinger, C Richez, GC Tsokos… - Nature Reviews …, 2023 - nature.com
Immune-mediated inflammatory diseases (IMIDs) are characterized by excessive and
uncontrolled inflammation and thrombosis, both of which are responsible for organ damage …
uncontrolled inflammation and thrombosis, both of which are responsible for organ damage …
Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014
M Scherlinger, P Mertz, F Sagez, A Meyer, R Felten… - Autoimmunity …, 2020 - Elsevier
Aim To describe changes in the 2001–2014 mortality of 6 autoimmune systemic diseases
(AISDs), namely Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Idiopathic …
(AISDs), namely Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Idiopathic …
New biologics and targeted therapies in systemic lupus: from new molecular targets to new indications. A systematic review
R Felten, M Scherlinger, P Mertz, F Chasset, L Arnaud - Joint Bone Spine, 2023 - Elsevier
Introduction Despite available therapies, persistently active and corticosteroid-dependent
Systemic Lupus Erythematosus (SLE) represent a significant therapeutic challenge. The …
Systemic Lupus Erythematosus (SLE) represent a significant therapeutic challenge. The …
[HTML][HTML] Refining “Long-COVID” by a prospective multimodal evaluation of patients with long-term symptoms attributed to SARS-CoV-2 infection
M Scherlinger, R Felten, F Gallais, C Nazon… - Infectious diseases and …, 2021 - Springer
Abstract Introduction COVID-19 long-haulers, also decribed as having “long-COVID” or post-
acute COVID-19 syndrome, represent 10% of COVID-19 patients and remain understudied …
acute COVID-19 syndrome, represent 10% of COVID-19 patients and remain understudied …
Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance
M Scherlinger, V Germain, C Labadie, T Barnetche… - Joint Bone Spine, 2018 - Elsevier
Objective To explore acceptance and retention rate of biosimilar CT-P13 after switching from
originator infliximab (OI) in patients with various rheumatic diseases. Methods Patients with …
originator infliximab (OI) in patients with various rheumatic diseases. Methods Patients with …
Phosphofructokinase P fine-tunes T regulatory cell metabolism, function, and stability in systemic autoimmunity
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by defective
regulatory T (Treg) cells. Here, we demonstrate that a T cell–specific deletion of …
regulatory T (Treg) cells. Here, we demonstrate that a T cell–specific deletion of …
[HTML][HTML] Effect of SARS-CoV-2 vaccination on symptoms from post-acute sequelae of COVID-19: results from the nationwide VAXILONG study
M Scherlinger, L Pijnenburg, E Chatelus, L Arnaud… - Vaccines, 2021 - mdpi.com
Introduction: Few data are available concerning the effect of SARS-CoV-2 vaccination on the
persistent symptoms associated with COVID-19, also called long-COVID or post-acute …
persistent symptoms associated with COVID-19, also called long-COVID or post-acute …
Systemic lupus erythematosus and systemic sclerosis: all roads lead to platelets
M Scherlinger, V Guillotin, ME Truchetet… - Autoimmunity …, 2018 - Elsevier
Systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) are two phenotypically
distincts inflammatory systemic diseases. However, SLE and SSc share pathogenic features …
distincts inflammatory systemic diseases. However, SLE and SSc share pathogenic features …
Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)
M Scherlinger, E Langlois, V Germain… - Seminars in Arthritis and …, 2019 - Elsevier
Objective To study acceptance rate and factors influencing acceptance of the switch from
originator etanercept (Enbrel©) to biosimilar etanercept (SB4, Bénépali©) in patients with …
originator etanercept (Enbrel©) to biosimilar etanercept (SB4, Bénépali©) in patients with …
Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases
R Felten, P Mertz, E Sebbag, M Scherlinger… - Drug Discovery …, 2023 - Elsevier
Drugs of unknown mechanisms of action are no longer being developed because we have
largely capitalized on our improved understanding of the immunopathogenesis of immune …
largely capitalized on our improved understanding of the immunopathogenesis of immune …